회사 개요
PepGen Inc. operates as a clinical-stage biotechnology firm dedicated to developing oligonucleotide therapeutics designed for the treatment of severe neuromuscular and neurologic diseases within the United States market. The company functions within the broader Healthcare sector, specifically targeting the specialized Biotechnology industry, where its focus is on advancing novel drug candidates like PGN-EDODM1, an EDO peptide-conjugated PMO currently undergoing Phase 2 clinical trials. In terms of corporate scale, PepGen maintains a market capitalization of $114.73M and employs a workforce of 56 individuals to support its research and development initiatives. The combination of a market cap under $120 million and an annual revenue figure listed as N/A indicates that PepGen is a pre-revenue entity typical of early-stage biotech firms, where valuation is primarily driven by pipeline potential rather than current cash generation or sales performance.
재무 건전성
The company's financial performance for the trailing twelve months shows a net income of $-89,655,000 and an EBITDA of $-92,215,000, while the revenue remains N/A, revealing a cost structure heavily weighted toward research and development expenses that exceed any current sales income. Free cash flow stands at $-49,845,500, indicating that the company is consuming cash reserves to fund its clinical operations rather than generating liquidity from commercial activities. All three key margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, which reflects the standard financial profile of a pre-revenue biotechnology company that has not yet achieved commercial product sales. Regarding capital structure, the company holds $148.46M in cash against $17.00M in debt, resulting in a debt-to-equity ratio of 11.53, suggesting a balance sheet that relies significantly on equity financing and cash holdings rather than substantial debt leverage despite the high ratio. The current ratio is an exceptionally high 11.94, indicating robust short-term liquidity relative to current liabilities, which provides a significant buffer for ongoing operational burn rates. Return on Equity is -67.4% and Return on Assets is -36.0%, metrics that demonstrate the company is currently in a capital-intensive growth phase where shareholder value is being diluted by investment costs rather than generated through profitability.
밸류에이션 평가
The valuation metrics present a complex picture given the lack of earnings, with a P/E Ratio (TTM) listed as N/A and a Forward P/E of -1.43, implying that analysts cannot value the stock based on current or projected earnings due to the negative earnings profile typical of the sector. The price-to-book ratio is 0.78, indicating that the market is valuing the company at less than its book value, which often occurs in biotech firms where intangible assets like intellectual property are not fully captured on the balance sheet. Alternative valuation multiples such as the Price to Sales ratio, which is N/A, and the EV/EBITDA of 0.18, further highlight the absence of traditional revenue and earnings drivers for standard multiple analysis. The stock has traded between a 52-week high of $7.80 and a 52-week low of $0.88, meaning the current price sits within this historical range, though the specific current price percentage is not calculable without real-time data. With a beta of 2.34, the stock exhibits high price volatility, moving more than twice as much as the broader market in response to sector-specific news or general market fluctuations.
Growth & Income
Revenue growth (YoY) and earnings growth (YoY) are both listed as N/A, reflecting the fact that the company has not yet generated consistent commercial revenue to establish a growth trajectory or earnings expansion rate. As a non-dividend payer, PepGen does not distribute a dividend yield or maintain a payout ratio, as the 0.0% payout ratio confirms that the company retains all available resources to reinvest into its clinical pipeline rather than returning capital to shareholders. This reinvestment strategy is characteristic of clinical-stage biotechnology companies that prioritize advancing drug candidates through development phases over providing immediate income to investors. Consequently, the overall growth and income profile for PepGen Inc. is defined by high operational expenditure and zero income distribution, relying entirely on future clinical success and potential regulatory approval to unlock value.